Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Interaction of synthetic opioid metenkephalin peptide analogs, lilly 127623 and FK 33-824 with indole hallucinogens: Antagonism of N,N-dimethyltryptamine- and LSD-induced disruption of food-rewarded bar pressing behavior in the rat

Abstract

The selected opioid metenkephalin synthetic peptide analogs Lilly (LY) 127623 and FK 33-824 were tested for behavioral dose effects and potential interaction with N,N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) in adult male Holtzman rats trained on a positive reinforcement fixed-ratio 4 (FR-4) behavioral bar pressing schedule, i.e., a reward of 0.01 ml sugar-sweetened evaporated milk was earned on every fourth bar press. DMT (3.2 mg/kg) and LSD (0.1 mg/kg), administered IP following a 0.9% NaCl 15–20-min control pretreatment, disrupted established food-rewarded FR-4 bar pressing in a consistent and reproducible manner. Animals pretreated IP with predetermined behaviorally noneffective doses of LY 127623 (0.01–0.32 mg/kg) and FK 33-824 (0.001–0.01 mg/kg) 15–20 min prior to receiving DMT demonstrated significant antagonism to DMT-induced disruption of FR-4 bar pressing, while doses of 0.10–0.32 mg/kg LY 127623 and 0.00032–0.0032 mg/kg FK 33-824 significantly antagonized LSD-induced behavioral effects.

This is a preview of subscription content, log in to check access.

References

  1. Ahn HS, Makman MH (1979) Interaction of LSD and other hallucinogens with dopamine-sensitive adenylate cyclase in primate brain: Regional differences. Brain Res 162:77–88

  2. Anokhina IP (1982) Several aspects of the interactions of the dopamine and opiate systems in schizophrenia. Vestn Akad Med Nauk USSR 1:37–40

  3. Barchas JD, Berger PA, Watson SJ, Akil H, Li CH (1980) Opioid agonists and antagonists in schizophrenia. Adv Biochem Psychopharmacol 22:447–453

  4. Beddell CR, Phil D, Lowe LA, Chem C, Wilkinson S (1980) Endogenous opioid peptides: The enkephalins and endorphins. In: Ellis GP, West GB (eds) Progress in medicinal chemistry, vol 17. Elsevier-North Holland Biomedical, pp 1–39

  5. Burt DR, Creese I, Snyder SH (1976) Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Mol Pharmacol 12:631–663

  6. Cristoph GR, Kuhn DM, Jacobs BL (1977) Electrophysiological evidence for a dopaminergic action of LSD: Depression of unit activity in the substantia nigra of the rat. Life Sci 21:1585–1590

  7. Domino EF, Ruffing DM (1982) Evidence for opioids as partial antagonists of indole hallucinogens. Psychopharmacol Bull 18:175–179

  8. Erdelyi E, Elliott GR, Wyatt RJ, Barchas JD (1979) S-Adenosylmethionine-dependent N-methyltransferase activity in autopsied brain parts of schizophrenics and controls. Am J Psychiatry 135:725–728

  9. Ferster CB, Skinner BF (1957) Schedules of reinforcement. Appleton Century Crofts, New York

  10. Frederickson RCA, Smithwick EL, Henry DP (1980) Opioid peptides as brain neurotransmitters with therapeutic potential: Basic and clinical studies. In: Marsan CA, Traczyk WZ (eds) Neuropeptides and neural transmission. Raven, New York, pp 227–235

  11. Fuxe K, Andersson K, Locatelli V, Agati LF, Mutt V, Eneroth P (1980) Effect of neuroactive drugs and neuropeptides on the hypothalamic catecholamine nerve terminal systems and on neuroendocrine functions. In: Miller R (ed) Neuroactive drugs in endocrinology. Elsevier-North Holland, Amsterdam, pp 149–166

  12. Gacel G, Fournie-Zaluski MC, Fellion E, Roques BP (1981) Evidence of the preferential involvement of μ receptors in analgesia using enkephalins highly selective for peripheral μ and δ receptors. J Med Chem 24:1119–1124

  13. Gesellchen PD, Zimmerman DM (1981) Analgesics (peripheral and central), endogenous opioids and their receptors. In: McDermed W (ed) Annual reports in medicinal chemistry, vol 16. Academic, New York, pp 41–49

  14. Glennon RA, Rosecrans JA (1981) Speculations on the mechanism of action of indolealkylamines. Neurosci Biobehav Rev 5:197–207

  15. Glennon RA, Liebowitz SM, Anderson III GM (1980) Serotonin receptor affinities of psychoactive phenalkylamine analogues. J Med Chem 23:294–299

  16. Jacobs BL, Trulson ME (1979) Mechanism of action of LSD. Am Sci 67:396–400

  17. Jacobs BL, Trulson ME (1981) An animal behavior model for decreased central serotonergic function. Adv Exp Med Biology 133:657–680

  18. Jenner P, Marsden CD, Thanki CM (1980) Behavioral changes induced by N,N-dimethyltryptamine in rodents. Br J Pharmacol 69:69–80

  19. Martin WR (1981) Multiple opioid receptors. Life Sci 28:1547–1554

  20. Marx JL (1981) Brain opiates in mental illness. Science 214:1013–1015

  21. Mehl E, Ruther E, Redmann J (1977) Endogenous ligands of a putative LSD-serotonin receptor in the cerebrospinal fluid: Higher level of LSD-displacing factors (LDF) in unmedicated psychotic patients. Psychopharmacology 54:9–16

  22. Morley JS (1980) Structure-activity relationships of enkephalin-like peptides. Annu Rev Pharmacol Toxicol 20:81–110

  23. Murray RM, Oon MCH, Rodnight R, Birley JLT, Smith BMA (1979) Increased excretion of dimethyltryptamine and certain features of psychosis. Arch Gen Psychiatry 36:644–649

  24. Nichols DE (1981) Structure-activity relationships of phenethylamine hallucinogens. J Pharm Sci 70:839–849

  25. Nielsen EB, Nielsen M, Ellison G, Braestrup C (1980) Decreased spiroperidol and LSD binding after continuous amphetamine. Eur J Pharmacol 66:149–154

  26. Olson GA, Olson RD, Kastin AJ, Coy DH (1981) Endogenous opiates: 1980. Peptides 2:349–369

  27. Peroutka SJ, Lebovitz RM, Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science 212:827–829

  28. van Praag HM, Verhoeven WMA (1980) Neuropeptides: A new dimension in biological psychiatry. In: Usdin E, Soukes TL, Youdim MBH (eds) Enzymes and neurotransmitters in mental disease. Wiley, New York, pp 1–34

  29. Rosenfeld MR, Makman MH (1981) The interaction of lisuride, an ergot derivative with serotonergic and dopaminergic receptors in rabbit brain. J Pharmacol Exp Ther 216:526–531

  30. Ruffing DM, Domino EF (1979) Naloxone enhancement of DMT- and LSD-25-induced suppression of food-rewarded bar pressing behavior in the rat. Psychopharmacology 62:207–210

  31. Ruffing DM, Domino EF (1981) Effects of selected opioid agonists and antagonists on DMT- and LSD-25-induced disruption of foodrewarded bar pressing behavior in the rat. Psychopharmacology 75:226–230

  32. Saavedra JM, Coyle JT, Axelrod J (1973). A specific and sensitive enzymatic assay for tryptamine in tissues. J Pharmacol Exp Ther 182:363–369

  33. Shulgin AT (1981) Hallucinogens. In: Wolff ME (ed) Burger's medicinal chemistry, part 3. Wiley, New York, pp 1109–1137

  34. Smythies JR, Morin RD, Brown GB (1979) Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography-mass spectrometry. Biol Psychiatry 14:549–556

  35. Snedecor GW, Cochran WG (1967) Statistical methods. Iowa State University Press, Ames, Iowa

  36. Stoff DM, Gillin JC, Wyatt RJ (1978) Animal models of drug-induced hallucinations. In: Stillman RC, Willette RE (eds) The psychopharmacology of hallucinogens. Pergamon, New York, pp 259–267

  37. Szara S (1982) Opiate receptors and endogenous opiates: Panorama of opiate research. Prog Neuropsychopharmacol Biol Psychiatry 6:3–15

  38. Terenius L, Wahlstrom A (1978) Physiological and clinical relevance of endorphins. In: Hughes J (ed) Centrally acting peptides. University Park, Baltimore, pp 161–178

  39. Trulson ME, Heym J, Jacobs BL (1981) Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats. Brain Res 215:275–293

  40. Usdin E, Bunney WE, Kline NS (1979) Endorphins in mental health research. Oxford University Press, New York

  41. Van Ree JM, deWied D (1981) Behavioral effects of beta-endorphin fragments. In: Rees LH, van Wimersma-Griedanus T (eds) Frontiers of hormone research, vol 8. Karger, Zurich, pp 178–192

  42. Verebey K (1981) Opioids and psychological disorders. Adv Alcohol Substance Abuse 1:101–123

  43. Von Hungen K, Roberts S, Hill DF (1975) Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain. Brain Res 94:57–66

  44. Wenger GR (1980) Cumulative dose-response curves in behavioral pharmacology. Pharmacol Biochem Behav 4:601–603

  45. deWied D (1980) Neuropeptides and psychopathology. Endeavour 4:154–159

Download references

Author information

Correspondence to Edward F. Domino.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ruffing, D.M., Domino, E.F. Interaction of synthetic opioid metenkephalin peptide analogs, lilly 127623 and FK 33-824 with indole hallucinogens: Antagonism of N,N-dimethyltryptamine- and LSD-induced disruption of food-rewarded bar pressing behavior in the rat. Psychopharmacology 80, 315–318 (1983). https://doi.org/10.1007/BF00432112

Download citation

Key words

  • Opioids
  • Metenkephalin
  • Peptides
  • LY 127623
  • FK 33-82324
  • DMT
  • LSD
  • Antagonism
  • Operant behavior